Select Medical Holdings (SEM) EBITDA (2018 - 2026)

Select Medical Holdings (SEM) has 9 years of EBITDA data on file, last reported at $98.4 million in Q1 2026.

• Quarterly EBITDA fell 12.71% year-over-year to $98.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $321.8 million (up 22.56% YoY) and the FY2025 annual result came in at $474.7 million, up 15.94% from the prior year.
• EBITDA grew to $98.4 million in Q1 2026 per SEM's latest filing, from $63.9 million in the prior quarter.
• Across five years, EBITDA topped out at $159.2 million in Q2 2023 and bottomed at -$173.4 million in Q4 2023.
• The 5-year median for EBITDA is $91.5 million (2022), against an average of $65.6 million.
• The widest annual swing landed in 2022, when EBITDA tumbled 321.39%; it then soared 203.14% in 2025.
• Tracing SEM's EBITDA over 5 years: stood at -$171.7 million in 2022, then slipped by 1.0% to -$173.4 million in 2023, then surged by 112.16% to $21.1 million in 2024, then soared by 203.14% to $63.9 million in 2025, then surged by 53.93% to $98.4 million in 2026.
• Per Business Quant, the three latest SEM EBITDA figures stand at $98.4 million (Q1 2026), $63.9 million (Q4 2025), and $73.0 million (Q3 2025).

Peer Comparison